Literature DB >> 22092728

Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation.

M Yamamoto1, Y Tochino, K Chibana, J B Trudeau, F Holguin, S E Wenzel.   

Abstract

BACKGROUND: Exhaled nitric oxide (FeNO) associates with asthma and eosinophilic inflammation. However, relationships between nitric oxide synthases, arginase, FeNO, asthma severity and inflammation remain poorly understood.
OBJECTIVES: To determine the relationships of iNOS expression/activation and arginase 2 expression with asthma severity, FeNO, nitrotyrosine (NT) and eosinophilic inflammation.
METHODS: Bronchial brushings and sputum were obtained from 25 normal controls, eight mild/no inhaled corticosteroids (ICS), 16 mild-moderate/with ICS and 35 severe asthmatics. The FeNO was measured the same day by ATS/ERS standards. The iNOS, arginase2 mRNA/protein and NT protein were measured in lysates from bronchial brushings by quantitative real-time PCR and Western blot. Induced sputum differentials were obtained.
RESULTS: Severe asthma was associated with the highest levels of iNOS protein and mRNA, although the index of iNOS mRNA to arginase2 mRNA most strongly differentiated severe from milder asthma. When evaluating NO-related enzyme functionality, iNOS mRNA/protein expression both strongly predicted FeNO (r = 0.61, P < 0.0001 for both). Only iNOS protein predicted NT levels (r = 0.48, P = 0.003) with the strongest relationship in severe asthma (r = 0.61, P = 0.009). The iNOS protein, FeNO and NT, all correlated with sputum eosinophils, but the relationships were again strongest in severe asthma. Controlling for arginase 2 mRNA/protein did not impact any functional outcome. CONCLUSIONS AND CLINICAL RELEVANCE: These data suggest that while iNOS expression from epithelial brushings is highest in severe asthma, factors controlling arginase2 mRNA expression significantly improve differentiation of severity. In contrast, functionality of the NO pathway as measured by FeNO, NT and eosinophilic inflammation, is strongly associated with iNOS expression alone, particularly in severe asthma.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092728      PMCID: PMC3650251          DOI: 10.1111/j.1365-2222.2011.03860.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  44 in total

1.  Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests.

Authors:  Christiane Lex; Flavia Ferreira; Angela Zacharasiewicz; Andrew G Nicholson; Patricia L Haslam; Nicola M Wilson; Trevor T Hansel; Donald N R Payne; Andrew Bush
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

2.  Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13.

Authors:  John Trudeau; Haizhen Hu; Kazuyuki Chibana; Hong Wei Chu; Jay Y Westcott; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2006-05-02       Impact factor: 10.793

3.  Glucocorticoids mediate the enhanced expression of intestinal type II arginase and argininosuccinate lyase in postweaning pigs.

Authors:  N E Flynn; C J Meininger; K Kelly; N H Ing; S M Morris; G Wu
Journal:  J Nutr       Date:  1999-04       Impact factor: 4.798

4.  Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma.

Authors:  Philip E Silkoff; Anne M Lent; Ashley A Busacker; Rohit K Katial; Silvana Balzar; Matthew Strand; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2005-11-08       Impact factor: 10.793

5.  The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.

Authors:  M A Berry; D E Shaw; R H Green; C E Brightling; A J Wardlaw; I D Pavord
Journal:  Clin Exp Allergy       Date:  2005-09       Impact factor: 5.018

Review 6.  The arginine-arginase balance in asthma and lung inflammation.

Authors:  Nives Zimmermann; Marc E Rothenberg
Journal:  Eur J Pharmacol       Date:  2006-02-03       Impact factor: 4.432

7.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.

Authors:  Sally Wenzel; Darren Wilbraham; Rick Fuller; Elise Burmeister Getz; Malinda Longphre
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

8.  Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide.

Authors:  Michele Miraglia del Giudice; Giorgio L Piacentini; Michele Capasso; Carlo Capristo; Nunzia Maiello; Attilio L Boner; Angelo F Capristo
Journal:  Respir Med       Date:  2007-04-05       Impact factor: 3.415

9.  Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells.

Authors:  Vinod Suresh; Justin D Mih; Steven C George
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-08       Impact factor: 6.914

10.  Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells.

Authors:  T Gotoh; M Mori
Journal:  J Cell Biol       Date:  1999-02-08       Impact factor: 10.539

View more
  30 in total

Review 1.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

2.  Proteomic analysis of the NOS2 interactome in human airway epithelial cells.

Authors:  Matthew W Foster; J Will Thompson; Michael T Forrester; Yonggang Sha; Timothy J McMahon; Dawn E Bowles; M Arthur Moseley; Harvey E Marshall
Journal:  Nitric Oxide       Date:  2013-02-21       Impact factor: 4.427

Review 3.  Emerging molecular phenotypes of asthma.

Authors:  Anuradha Ray; Timothy B Oriss; Sally E Wenzel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-17       Impact factor: 5.464

4.  IL-27 and type 2 immunity in asthmatic patients: association with severity, CXCL9, and signal transducer and activator of transcription signaling.

Authors:  Min Xie; Anthony T Mustovich; Yi Jiang; John B Trudeau; Anuradha Ray; Prabir Ray; Haizhen Hu; Fernando Holguin; Bruce Freeman; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2014-10-11       Impact factor: 10.793

5.  Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program.

Authors:  Kenneth Wysocki; Seo Young Park; Eugene Bleecker; William Busse; Mario Castro; Kian Fan Chung; Benjamin Gaston; Serpil Erzurum; Elliot Israel; W Gerald Teague; Charity G Moore; Sally Wenzel
Journal:  J Allergy Clin Immunol       Date:  2013-12-09       Impact factor: 10.793

6.  Myeloid-derived suppressor cells (MDSCs) and mechanistic target of rapamycin (mTOR) signaling pathway interact through inducible nitric oxide synthase (iNOS) and nitric oxide (NO) in asthma.

Authors:  Yanli Zhang; Boyi Xu; Bin Luan; Yan Zhang; Yanling Li; Xiaorong Xiong; Hongke Shi
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 7.  Genetics of chronic rhinosinusitis: state of the field and directions forward.

Authors:  Joy Hsu; Pedro C Avila; Robert C Kern; M Geoffrey Hayes; Robert P Schleimer; Jayant M Pinto
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

8.  Phenotypic and genotypic association of epithelial IL1RL1 to human TH2-like asthma.

Authors:  Russell S Traister; Crystal E Uvalle; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2014-08-01       Impact factor: 10.793

Review 9.  Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?

Authors:  Julie G Ledford; Kenneth J Addison; Matthew W Foster; Loretta G Que
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

10.  Mind-body interactions in the regulation of airway inflammation in asthma: A PET study of acute and chronic stress.

Authors:  Melissa A Rosenkranz; Stephane Esnault; Bradley T Christian; Gina Crisafi; Lauren K Gresham; Andrew T Higgins; Mollie N Moore; Sarah M Moore; Helen Y Weng; Rachel H Salk; William W Busse; Richard J Davidson
Journal:  Brain Behav Immun       Date:  2016-03-30       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.